Thursday, August 6, 2026

Alteogen Signs $365 Million License Deal With Global Pharma Company for SC Platform Technology

Alteogen has signed an exclusive licensing agreement with a global pharmaceutical company for the development of subcutaneous biopharmaceuticals.

Samsung vs. LG: The Race to Control the AI-Powered Car Cabin in the Autonomous Era

Samsung and LG compete in automotive tech, focusing on displays and infotainment as key to vehicle competitiveness.

May 2026: What Will Trump and Putin’s Visits to China Mean for North Korea?

Diplomatic tensions rise as Trump and Putin plan visits to China, potentially impacting U.S.-North Korea relations and South Korea's strategy.

Health

5 Key Research Findings on Dr. Noon CVD: A Game-Changer for Cardiovascular Disease Prevention

Mediwhale presented five abstracts on its AI-based cardiovascular risk assessment solution, Dr. Noon CVD, at the ASPC conference.

“Improved Survival Rates”… Carboplatin Combination Therapy Shows Benefit in Triple-Negative Breast Cancer

Adding carboplatin to chemotherapy for operable triple-negative breast cancer reduces recurrence risk and improves survival, study finds.

Inventage Lab Selected for Global TIPS Program, Accelerating Late-Stage Development of Addiction Treatment

Inventis Lab's long-acting drug IVL3004 for addiction treatment has been selected for the Global TIPS research project by the Ministry of SMEs.

Bukwang Pharm Signs Export Agreement With Thailand’s Pacific Healthcare for Dexid

Bukwang Pharmaceutical signs exclusive export contract for diabetes treatment 'Dexide' with Pacific Healthcare in Thailand.

Huawei Unveils OpenPangu 2.0 Pro: Is This the Future of AI with 505 Billion Parameters?

Huawei accelerates its AI ecosystem expansion by revealing the source of its massive AI model with over 500 billion parameters.
Latest

Global Pharma Giants Join Samsung Biologics in Major Climate Pledge to Cut Supply-Chain Emissions by 2030

Samsung Biologics leads a global initiative to reduce carbon emissions in healthcare, aiming for sustainability and renewable energy by 2030.

TRUST ME, I’m an Expert: Trump’s Tylenol-Autism Claim Exposes Washington’s Dangerous NEW Brand of Idiocy

Trump claims Tylenol during pregnancy may raise autism risk, but medical experts refute this as unsupported by scientific evidence.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns rise over South Korea's API industry reliance on China and India, with self-sufficiency at a record low of 25.6% in 2023.

Samsung Biologics Targets Japan’s $12.3 Billion CDMO Market: What You Need to Know

Samsung Biologics expands in Japan, targeting top pharma firms with new CMO brand 'ExellenS' and enhancing production capabilities.

Lotte Biologics Unveils Dual-Site Strategy: A Game Changer for Global CDMO in 2027

Lotte Biologics aims to lead in the evolving biotech landscape with dual sites in the U.S. and South Korea, enhancing global supply chains.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

Fever’s Bigger Risk: Why the Tylenol Controversy Puts Moms in a Bind

Controversy surrounds acetaminophen use during pregnancy and its alleged link to autism, but evidence remains inconclusive.

Is Tylenol Dangerous for Pregnant Women? Trump’s Controversial Claims Debunked by Experts

UK Health Secretary counters Trump's claim linking Tylenol to autism, affirming its safety for pregnant women based on scientific studies.

Trump’s Next Target: Big Pharma’s Tylenol. Why He’s Questioning a $1B Industry

Trump links Tylenol to autism risk, announcing new FDA guidelines and studies, but scientific consensus remains unestablished.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Bio-Revolution: Celltrion’s $700M Biosimilar Is Reshaping the Global Drug Market

Celltrion's breakthrough in antibody biosimilars is transforming healthcare, enhancing access and innovation in treatment options.

Sales and Trust: How Celltrion is Revolutionizing the European Market Directly Connected

Celltrion leverages direct sales in Europe to enhance trust and supply stability while introducing biosimilars like Omlyclo for asthma treatment.

Tylenol Stock Plunges: Trump’s Autism Warning Rattles $17B Market

Tylenol faces scrutiny over potential autism link during pregnancy, with mixed responses from the medical community and FDA caution.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.